415 related articles for article (PubMed ID: 9025759)
1. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
[TBL] [Abstract][Full Text] [Related]
2. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy.
Giap HB; Macey DJ; Podoloff DA
J Nucl Med; 1995 Oct; 36(10):1885-94. PubMed ID: 7562060
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging.
Flux GD; Webb S; Ott RJ; Chittenden SJ; Thomas R
J Nucl Med; 1997 Jul; 38(7):1059-66. PubMed ID: 9225791
[TBL] [Abstract][Full Text] [Related]
4. Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution.
Akabani G; Hawkins WG; Eckblade MB; Leichner PK
J Nucl Med; 1997 Feb; 38(2):308-14. PubMed ID: 9025760
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
6. 3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.
Saeedzadeh E; Sarkar S; Abbaspour Tehrani-Fard A; Ay MR; Khosravi HR; Loudos G
Radiat Prot Dosimetry; 2012 Jul; 150(3):298-305. PubMed ID: 22069233
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional dosimetry for radioimmunotherapy treatment planning.
Sgouros G; Chiu S; Pentlow KS; Brewster LJ; Kalaigian H; Baldwin B; Daghighian F; Graham MC; Larson SM; Mohan R
J Nucl Med; 1993 Sep; 34(9):1595-601. PubMed ID: 8394886
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry.
Yoriyaz H; Stabin MG; dos Santos A
J Nucl Med; 2001 Apr; 42(4):662-9. PubMed ID: 11337557
[TBL] [Abstract][Full Text] [Related]
9. A radionuclide therapy treatment planning and dose estimation system.
Liu A; Williams LE; Lopatin G; Yamauchi DM; Wong JY; Raubitschek AA
J Nucl Med; 1999 Jul; 40(7):1151-3. PubMed ID: 10405136
[TBL] [Abstract][Full Text] [Related]
10. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
[TBL] [Abstract][Full Text] [Related]
11. On the need to revise the arm structure in stylized anthropomorphic phantoms in lateral photon irradiation geometry.
Lee C; Lee C; Lee JK
Phys Med Biol; 2006 Nov; 51(21):N393-402. PubMed ID: 17047258
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
Prideaux AR; Song H; Hobbs RF; He B; Frey EC; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2007 Jun; 48(6):1008-16. PubMed ID: 17504874
[TBL] [Abstract][Full Text] [Related]
13. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides.
Sgouros G; Barest G; Thekkumthala J; Chui C; Mohan R; Bigler RE; Zanzonico PB
J Nucl Med; 1990 Nov; 31(11):1884-91. PubMed ID: 2231006
[TBL] [Abstract][Full Text] [Related]
14. Registration of serial SPECT/CT images for three-dimensional dosimetry in radionuclide therapy.
Sjögreen-Gleisner K; Rueckert D; Ljungberg M
Phys Med Biol; 2009 Oct; 54(20):6181-200. PubMed ID: 19794243
[TBL] [Abstract][Full Text] [Related]
15. Murine S factors for liver, spleen, and kidney.
Kolbert KS; Watson T; Matei C; Xu S; Koutcher JA; Sgouros G
J Nucl Med; 2003 May; 44(5):784-91. PubMed ID: 12732681
[TBL] [Abstract][Full Text] [Related]
16. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
17. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
Mangili P; Stea L; Cattani F; Lappi S; Giglioli F; Calamia E; Ziglio F; Martinelli R; Longobardi B
Radiother Oncol; 2004 Apr; 71(1):13-21. PubMed ID: 15066291
[TBL] [Abstract][Full Text] [Related]
19. Canine anatomic phantom for preclinical dosimetry in internal emitter therapy.
Padilla L; Lee C; Milner R; Shahlaee A; Bolch WE
J Nucl Med; 2008 Mar; 49(3):446-52. PubMed ID: 18287264
[TBL] [Abstract][Full Text] [Related]
20. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
